Daptomycin vs. Vancomycin for MRSA Bacteremia with Elevated Vancomycin MICs

In a retrospective, matched cohort study involving 170 patients, the risk for treatment failure at 30 days was significantly increased in those receiving vancomycin.

With increasing use of vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) infections have come reports of MRSA isolates with vancomycin minimum inhibitory concentrations (MICs) >1 µg/mL — and of treatment failures at these elevated MICs.

To examine the situation, researchers (some with ties to the manufacturer of daptomycin) performed a retrospective, matched cohort study comparing outcomes of adults with MRSA bacteremia (MRSAB) who were treated with vancomycin or daptomycin at any of four Detroit hospitals between January 2005 and March 2012. Beginning in February 2008, patients with MRSAB were to receive daptomycin if the vancomycin MIC was >1 and ≤2 µg/mL. Daptomycin-treated patients received ≥6 mg/kg daily, as determined b…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)